Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 17-Sep-2025 18:11 ET (17-Sep-2025 22:11 GMT/UTC)